These results, together with the fact that aptamers, due to their nucleotide nature, usually show low or no immunogenicity or toxicity, make the apHAT610 aptamer targeting HAT1 a better alternative for further development as an antitumor agent in lung cancer and other tumors. This evidence concerns the gene HAT1 and lung cancer.